Analysis of one-year follow-up results and treatment costs of patients with PTE in a tertiary care center.

IF 0.7 Q4 RESPIRATORY SYSTEM
Ersin Ergül, Elif Yılmazel Uçar, Ömer Araz, Alperen Aksakal, Buğra Kerget, Leyla Sağlam
{"title":"Analysis of one-year follow-up results and treatment costs of patients with PTE in a tertiary care center.","authors":"Ersin Ergül, Elif Yılmazel Uçar, Ömer Araz, Alperen Aksakal, Buğra Kerget, Leyla Sağlam","doi":"10.5578/tt.20239607","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Pulmonary thromboembolism (PTE) is a life-threatening disease, with substantial treatment-related complications, difficult follow-up, treatment compliance, and high costs. This study aimed to assess treatment costs with various maintenance therapy regimens, complications, and patient adherence to treatment over a one-year follow-up period.</p><p><strong>Materials and methods: </strong>This observational, prospective study included 142 patients with PTE who received maintenance anticoagulation therapy between November 2020 and March 2023. The patients were observed at three-month intervals for a year. Possible treatment-related complications, recurrence, mortality, and treatment costs were recorded.</p><p><strong>Result: </strong>Our results showed that there was no significant difference in bleeding risk based on the drugs used for initial or maintenance treatment. In maintenance therapy, low-molecular-weight heparin (LMWH), warfarin, and direct oral anticoagulant (DOAC) treatment regimens had similar treatment adherence and comparable efficacy and safety in terms of recurrence and bleeding (p> 0.05). Four patients (2.8%) were diagnosed with chronic thromboembolic disease. The one-year mortality rate was 24.6% (n= 35), of which 82.9% (n= 29) occurred within the first three months. Hospital mortality rates with the different maintenance therapies were 8.8% in the LMWH group, 5.7% in the warfarin group, and 3.2% in the DOAC group. The annual cost of using LMWH was higher than that of rivaroxaban, apixaban, and warfarin (p< 0.001) while there was no significant cost difference between DOACs and warfarin (p> 0.05).</p><p><strong>Conclusions: </strong>In our study, the LMWH, warfarin, and DOAC treatment regimens had similar efficacy, safety, and patient compliance. In terms of cost, LMWH was the costliest while DOAC and warfarin were similar.</p>","PeriodicalId":45521,"journal":{"name":"Tuberkuloz ve Toraks-Tuberculosis and Thorax","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11390067/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tuberkuloz ve Toraks-Tuberculosis and Thorax","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5578/tt.20239607","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Pulmonary thromboembolism (PTE) is a life-threatening disease, with substantial treatment-related complications, difficult follow-up, treatment compliance, and high costs. This study aimed to assess treatment costs with various maintenance therapy regimens, complications, and patient adherence to treatment over a one-year follow-up period.

Materials and methods: This observational, prospective study included 142 patients with PTE who received maintenance anticoagulation therapy between November 2020 and March 2023. The patients were observed at three-month intervals for a year. Possible treatment-related complications, recurrence, mortality, and treatment costs were recorded.

Result: Our results showed that there was no significant difference in bleeding risk based on the drugs used for initial or maintenance treatment. In maintenance therapy, low-molecular-weight heparin (LMWH), warfarin, and direct oral anticoagulant (DOAC) treatment regimens had similar treatment adherence and comparable efficacy and safety in terms of recurrence and bleeding (p> 0.05). Four patients (2.8%) were diagnosed with chronic thromboembolic disease. The one-year mortality rate was 24.6% (n= 35), of which 82.9% (n= 29) occurred within the first three months. Hospital mortality rates with the different maintenance therapies were 8.8% in the LMWH group, 5.7% in the warfarin group, and 3.2% in the DOAC group. The annual cost of using LMWH was higher than that of rivaroxaban, apixaban, and warfarin (p< 0.001) while there was no significant cost difference between DOACs and warfarin (p> 0.05).

Conclusions: In our study, the LMWH, warfarin, and DOAC treatment regimens had similar efficacy, safety, and patient compliance. In terms of cost, LMWH was the costliest while DOAC and warfarin were similar.

一家三级医疗中心对 PTE 患者一年随访结果和治疗费用的分析。
简介:肺血栓栓塞症(PTE)是一种威胁生命的疾病:肺血栓栓塞症(PTE)是一种威胁生命的疾病,与治疗相关的并发症多、随访困难、治疗依从性差且费用高昂。本研究旨在评估各种维持治疗方案的治疗费用、并发症以及患者在一年随访期内的治疗依从性:这项前瞻性观察研究纳入了 142 名在 2020 年 11 月至 2023 年 3 月期间接受维持性抗凝治疗的 PTE 患者。每隔三个月对患者进行一次为期一年的观察。研究记录了可能与治疗相关的并发症、复发率、死亡率和治疗费用:结果:我们的研究结果表明,初始治疗和维持治疗所使用的药物在出血风险方面没有明显差异。在维持治疗中,低分子量肝素(LMWH)、华法林和直接口服抗凝剂(DOAC)治疗方案的治疗依从性相似,在复发和出血方面的疗效和安全性相当(P> 0.05)。四名患者(2.8%)被诊断为慢性血栓栓塞性疾病。一年死亡率为 24.6%(35 人),其中 82.9%(29 人)发生在头三个月。采用不同维持疗法的医院死亡率分别为:LMWH 组 8.8%、华法林组 5.7%、DOAC 组 3.2%。使用LMWH的年成本高于利伐沙班、阿哌沙班和华法林(P< 0.001),而DOAC与华法林之间没有显著的成本差异(P> 0.05):在我们的研究中,LMWH、华法林和 DOAC 治疗方案具有相似的疗效、安全性和患者依从性。就成本而言,LMWH 的成本最高,而 DOAC 和华法林的成本相近。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.50
自引率
9.10%
发文量
43
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信